Affinage

YTHDF2

YTH domain-containing family protein 2 · UniProt Q9Y5A9

Length
579 aa
Mass
62.3 kDa
Annotated
2026-04-28
100 papers in source corpus 43 papers cited in narrative 44 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

YTHDF2 is a cytoplasmic m6A reader protein that serves as a central post-transcriptional regulator, primarily accelerating mRNA decay but also modulating translation and miRNA maturation in a context-dependent manner. Its canonical function involves binding m6A-modified mRNAs through its YTH domain and recruiting the CCR4-NOT deadenylase complex to promote deadenylation and degradation of target transcripts — a mechanism demonstrated across hematopoietic stem cells, immune cells, germ cells, and multiple cancer types (PMID:32905781, PMID:31031138, PMID:34850470). Beyond decay, YTHDF2 enhances translation of specific m6A-modified mRNAs by recruiting eIF3B or forming a complex with eIF3F and DDX1 (PMID:38247171, PMID:40480228), stabilizes m5C-modified mRNAs through PABPC1 recruitment (PMID:39694037), and operates in the nucleus to sustain transcription via interaction with IKZF1/3 in CD8+ T cells (PMID:39500904). YTHDF2 protein stability and activity are extensively regulated by post-translational modifications — including EGFR/SRC/ERK-mediated phosphorylation at S39/T381 (PMID:33420027), SUMOylation at K571 that enhances m6A-RNA binding under hypoxia (PMID:33577677), O-GlcNAcylation at S263 that blocks ubiquitination (PMID:36765030), CDK1-dependent stabilization during mitosis (PMID:32267835), and proteasomal degradation directed by FBW7, CUL1/CUL4A–DDB1–SKP2, and STUB1 E3 ligase complexes (PMID:33658012, PMID:32267835, PMID:37515378).

Mechanistic history

Synthesis pass · year-by-year structured walk · 24 steps
  1. 2018 High

    Establishing YTHDF2 as a physiological regulator of HSC self-renewal resolved how m6A-dependent mRNA turnover controls stem cell pool size — YTHDF2 loss stabilized m6A-marked transcription factor mRNAs (e.g., Tal1), expanding functional HSCs ex vivo and in vivo.

    Evidence Conditional Ythdf2 KO mouse with limiting-dilution transplantation and m6A-seq in HSPCs

    PMID:30065315

    Open questions at the time
    • Identity of all HSC-relevant YTHDF2 target mRNAs not fully catalogued
    • Whether YTHDF2 acts exclusively through decay in HSCs or also through translational regulation was not addressed
  2. 2018 Medium

    Demonstrating that YTHDF2 binds m6A sites in EGFR 3′-UTR and accelerates EGFR mRNA degradation linked YTHDF2-mediated decay to oncogenic signaling suppression in hepatocellular carcinoma.

    Evidence m6A-RIP, RNA stability assay, and downstream MEK/ERK signaling readouts in HCC cells

    PMID:30423408

    Open questions at the time
    • Single-lab study without independent replication
    • Structural basis of YTHDF2 selectivity for EGFR mRNA over other m6A targets not determined
  3. 2019 High

    Identification of Tnfrsf2 as a YTHDF2-degraded target in AML established that YTHDF2 suppresses apoptotic priming in leukemic stem cells, providing a disease-specific mechanistic rationale for targeting YTHDF2 in AML.

    Evidence m6A-seq, RNA stability assays, conditional KO mouse models, human AML xenograft transplantation

    PMID:31031138

    Open questions at the time
    • Whether all AML subtypes depend on YTHDF2 equally was not tested
    • Redundancy with YTHDF1/3 in AML context not resolved
  4. 2019 Medium

    Discovery that YTHDF2 recognizes m1A in addition to m6A broadened the epitranscriptomic reader specificity of the YTH domain beyond a single modification.

    Evidence Chemical proteomics pulldown and recombinant protein binding assay with m1A probes, followed by cellular knockdown

    PMID:31815430

    Open questions at the time
    • Structural basis for m1A recognition not resolved
    • Physiological relevance of m1A reading in vivo not established
  5. 2019 Medium

    Showing that YTHDF2 knockdown in macrophages stabilizes MAP2K4/MAP4K4 mRNAs and hyperactivates MAPK/NF-κB signaling revealed YTHDF2 as a tonic suppressor of inflammatory gene expression programs.

    Evidence siRNA knockdown, mRNA stability assay, signaling pathway inhibitors in LPS-stimulated macrophages

    PMID:30875984

    Open questions at the time
    • Macrophage-specific YTHDF2 KO was not used
    • Direct m6A-RIP on MAP2K4/MAP4K4 not performed in this study
  6. 2020 High

    The CDK1–YTHDF2–WEE1 feedforward loop established that YTHDF2-mediated mRNA decay is integrated into cell cycle control: CDK1 stabilizes YTHDF2, which degrades WEE1 mRNA to accelerate mitotic entry, while CUL1/CUL4A–DDB1–SKP2 E3 complexes degrade YTHDF2 to reset the cycle.

    Evidence siRNA depletion, m6A-seq, RNA stability assay, CDK1 inhibitor treatment, co-IP with E3 ligase components

    PMID:32267835

    Open questions at the time
    • Direct phosphorylation of YTHDF2 by CDK1 not demonstrated
    • Relative contributions of CUL1 vs CUL4A complexes not disentangled
  7. 2020 High

    Establishing that YTHDF2 recruits the CCR4-NOT deadenylase complex to degrade somatic gene mRNAs during iPSC reprogramming defined the effector mechanism for YTHDF2-mediated mRNA clearance.

    Evidence CRISPR/siRNA KD in reprogramming, scRNA-seq, co-IP with CCR4-NOT subunits, mRNA stability assay

    PMID:32905781

    Open questions at the time
    • Whether CCR4-NOT is the universal YTHDF2 decay effector or context-specific was not resolved
    • Contribution of YTHDF3 versus YTHDF2 to CCR4-NOT recruitment not fully separated
  8. 2021 High

    Mapping EGFR/SRC/ERK-dependent phosphorylation of YTHDF2 at S39 and T381 revealed how oncogenic signaling stabilizes the reader protein, amplifying m6A-dependent mRNA decay in glioblastoma.

    Evidence Phosphorylation mapping by mass spectrometry, site-directed mutagenesis, RIP, m6A-seq, in vivo tumorigenesis

    PMID:33420027

    Open questions at the time
    • Whether phosphorylation alters YTHDF2 substrate specificity or just abundance was not clarified
    • Kinase-dead rescue experiments not performed
  9. 2021 High

    Identification of K571 SUMOylation as a hypoxia-induced modification that increases YTHDF2's m6A-binding affinity without affecting stability established a distinct post-translational control axis that tunes reader activity rather than abundance.

    Evidence In vitro and in vivo SUMOylation assays, K571 mutagenesis, m6A-RIP, mRNA stability assay

    PMID:33577677

    Open questions at the time
    • SUMO E3 ligase identity not determined
    • Whether SUMOylation affects YTHDF2 interactome (e.g., CCR4-NOT recruitment) not tested
  10. 2021 High

    Demonstrating that FBW7 targets YTHDF2 for proteasomal degradation added a tumor-suppressive E3 ligase axis to YTHDF2 regulation, connecting FBW7 loss in ovarian cancer to aberrant m6A-reader accumulation.

    Evidence IP-mass spectrometry, co-IP, ubiquitination assays, in vitro/in vivo tumorigenesis, m6A-RIP-seq

    PMID:33658012

    Open questions at the time
    • FBW7 degron motif on YTHDF2 not mapped
    • Whether FBW7-mediated regulation is phosphodegron-dependent (as for canonical FBW7 substrates) not determined
  11. 2021 High

    Ythdf2 conditional KO in HSCs revealed chronic upregulation of m6A-modified inflammation transcripts, establishing YTHDF2 as a guardian that dampens inflammatory signaling to preserve HSC fitness during stress.

    Evidence Conditional Ythdf2 KO mouse, serial transplantation, transcriptomic profiling, experimental inflammation

    PMID:33156926

    Open questions at the time
    • Whether anti-inflammatory function of YTHDF2 in HSCs is separable from its role in self-renewal not tested
    • Direct demonstration that specific inflammation transcripts are m6A-marked and YTHDF2-bound was limited
  12. 2021 High

    Germ cell-specific Ythdf2 KO demonstrated male infertility from failure to clear phase-specific transcripts during spermatogenesis, establishing a non-redundant developmental role for YTHDF2 in germ cell differentiation.

    Evidence Multiple Cre drivers (Vasa-Cre, Stra8-Cre), RIP-seq, MeRIP-qPCR, fertility assays

    PMID:34850470

    Open questions at the time
    • Redundancy with YTHDF1/3 in spermatogenesis not systematically addressed
    • Whether YTHDF2 acts solely through decay or also translation in spermatocytes not resolved
  13. 2021 High

    A CRISPR screen in TNBC revealed that YTHDF2 is essential for cancer cell viability: its loss stabilizes MAPK pathway mRNAs, induces EMT, increases global translation, and triggers lethal ER stress — demonstrating that YTHDF2 buffers translational homeostasis.

    Evidence Pooled CRISPR screen, eCLIP, m6A-seq, scRibo-STAMP, in vivo tumor models

    PMID:34216543

    Open questions at the time
    • Whether ER stress is a universal consequence of YTHDF2 loss or TNBC-specific not established
    • Mechanism linking stabilized mRNAs to increased global translation not fully resolved
  14. 2022 High

    Structural determination of small-molecule fragments bound to the YTHDF2 YTH domain m6A pocket enabled pharmacological targeting, providing the first atomic-resolution view of druggable YTHDF2 interfaces.

    Evidence X-ray crystallography and fluorescence-based competitive binding assay

    PMID:36110386

    Open questions at the time
    • No cell-active inhibitor demonstrated
    • Fragment affinity was modest; drug-like optimization not achieved
  15. 2022 High

    B cell-specific Ythdf2 KO showed failure of GC B cell commitment because plasmablast-program transcripts were not cleared, revealing YTHDF2 as a fate switch in humoral immunity.

    Evidence Conditional B-cell Ythdf2 KO, scRNA-seq, YTHDF2 binding-site analysis, in vivo GC response

    PMID:35508130

    Open questions at the time
    • Whether YTHDF2 also functions at later GC stages (e.g., affinity maturation) not investigated
    • Specific m6A sites on plasmablast transcripts not mapped at nucleotide resolution
  16. 2023 High

    O-GlcNAcylation of YTHDF2 at S263 by OGT was shown to stabilize YTHDF2 by blocking ubiquitination, linking nutrient sensing to m6A-reader abundance and cell cycle progression via MCM2/MCM5 mRNA stabilization.

    Evidence MS identification of S263 O-GlcNAcylation, site-directed mutagenesis, OGT inhibitor, MeRIP, RNA stability assay

    PMID:36765030

    Open questions at the time
    • Which E3 ligase is blocked by O-GlcNAcylation at S263 not identified
    • Whether S263 O-GlcNAcylation affects YTHDF2 RNA-binding specificity not tested
  17. 2023 High

    Myeloid-specific Ythdf2 KO reprogrammed tumor-associated macrophages toward antitumoral phenotypes via IFN-γ–STAT1 signaling, and YTHDF2 expression was regulated by IL-10–STAT3, establishing a macrophage-intrinsic m6A-dependent immune checkpoint.

    Evidence Myeloid-specific Ythdf2 KO, flow cytometry, in vivo tumor models, STAT1/STAT3 signaling analysis

    PMID:36658237

    Open questions at the time
    • Specific m6A-modified STAT1 pathway mRNAs targeted by YTHDF2 not comprehensively identified
    • Whether this mechanism operates across all tumor types not tested
  18. 2023 High

    An IR–YTHDF2–NF-κB feedforward circuit in MDSCs demonstrated that ionizing radiation induces YTHDF2 via NF-κB, and YTHDF2 then degrades negative regulators of NF-κB, amplifying immunosuppression.

    Evidence Myeloid-specific Ythdf2 KO, RNA-seq, m6A-RIP, in vivo tumor irradiation, NF-κB inhibitor

    PMID:37236197

    Open questions at the time
    • Identities of all NF-κB negative regulators targeted by YTHDF2 not exhaustively mapped
    • Therapeutic window for combining YTHDF2 inhibition with radiotherapy not defined
  19. 2023 Medium

    HSP90β was shown to competitively block STUB1-mediated ubiquitination of YTHDF2, adding a chaperone-dependent stabilization mechanism to the growing repertoire of YTHDF2 post-translational regulation.

    Evidence Reciprocal co-IP, domain mapping, ubiquitination assay, HSP90 inhibitor treatment in HCC

    PMID:37515378

    Open questions at the time
    • Whether HSP90β stabilization of YTHDF2 is constitutive or signal-regulated not determined
    • Interaction interface on YTHDF2 not mapped
  20. 2024 High

    Discovery that YTHDF2 recognizes m5C-modified mRNAs and stabilizes them by recruiting PABPC1 — opposite to its canonical m6A-mediated decay — established YTHDF2 as a dual-modification reader with modification-dependent functional polarity, driving B cell malignancy.

    Evidence RIP-seq, m5C-seq, co-IP with PABPC1, mRNA stability assays, YTHDF2 OE/KO in B cell transformation models

    PMID:39694037

    Open questions at the time
    • Structural basis for m5C recognition by the YTH domain not determined
    • Whether m5C reading by YTHDF2 operates broadly or is restricted to B cell lineage not tested
  21. 2024 High

    Identification of a YTHDF2–eIF3F–DDX1 translation complex demonstrated a decay-independent translational enhancement function for YTHDF2 on m6A-modified mRNAs encoding microtubule-associated proteins, explaining paclitaxel resistance.

    Evidence Co-IP of complex components, polysome profiling, m6A-seq, RNA stability assay ruling out decay, in vivo tumor models

    PMID:40480228

    Open questions at the time
    • Whether eIF3F/DDX1 complex is the same as the eIF3B-dependent translation pathway reported in HCC not clarified
    • Structural basis of YTHDF2–eIF3F interaction unknown
  22. 2024 High

    Nuclear YTHDF2 in CD8+ T cells was shown to promote nascent RNA synthesis by interacting with IKZF1/3 and sustaining their transcriptional programs, expanding YTHDF2's functional repertoire beyond cytoplasmic mRNA fate determination.

    Evidence T cell-specific KO, ChIP-seq, m6A-seq, YTHDF2 co-IP with IKZF1/3, nascent RNA assays, in vivo lenalidomide rescue

    PMID:39500904

    Open questions at the time
    • Whether nuclear YTHDF2 directly contacts chromatin or acts through IKZF1/3 intermediaries not resolved
    • How YTHDF2 nuclear import is regulated remains unknown
  23. 2024 High

    IFN-γ-induced autophagic degradation of tumoral YTHDF2 was shown to sensitize tumors to CD8+ T cell killing, revealing a non-proteasomal degradation pathway that connects immune cytokine signaling to m6A reader abundance in the tumor microenvironment.

    Evidence Tumoral Ythdf2 KO, co-culture assays, autophagy inhibitors, metabolic assays, in vivo immunocompetent models

    PMID:38820140

    Open questions at the time
    • Selective autophagy receptor mediating YTHDF2 degradation not identified
    • Whether autophagic degradation of YTHDF2 operates in non-tumor cell types not tested
  24. 2024 High

    YTHDF2-dependent decay of TGF-β pathway mRNAs in hippocampal neural stem cells demonstrated that YTHDF2 controls the balance between NSC activation and quiescence, extending its stem cell regulatory role beyond the hematopoietic system.

    Evidence Conditional Ythdf2 KO in NSCs, m6A-seq, YTHDF2-RIP-seq, mRNA decay profiling, TGF-β inhibitor rescue

    PMID:39476834

    Open questions at the time
    • Whether YTHDF2 regulates NSC quiescence in aging or disease contexts not tested
    • Redundancy with YTHDF1/3 in NSCs not addressed

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include: (1) the structural basis for YTHDF2's dual recognition of m6A and m5C and how modification identity switches its output from decay to stabilization; (2) how nuclear versus cytoplasmic YTHDF2 pools are partitioned and whether translational, transcriptional, and decay functions are mutually exclusive or co-occurring; (3) whether the multiple E3 ligase systems (FBW7, SKP2, STUB1) and post-translational modifications act hierarchically or in parallel across tissues.
  • No structural model for m5C recognition by YTH domain
  • Nuclear import/export mechanism undetermined
  • Integrated model of PTM crosstalk on YTHDF2 lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0003723 RNA binding 6 GO:0140098 catalytic activity, acting on RNA 4 GO:0098772 molecular function regulator activity 2 GO:0140110 transcription regulator activity 1
Localization
GO:0005829 cytosol 4 GO:0005634 nucleus 2
Pathway
R-HSA-8953854 Metabolism of RNA 6 R-HSA-168256 Immune System 4 R-HSA-162582 Signal Transduction 3 R-HSA-392499 Metabolism of proteins 3 R-HSA-1640170 Cell Cycle 2 R-HSA-5357801 Programmed Cell Death 2
Partners
CNOT1DDX1EIF3BEIF3FFBW7HSP90AB1IKZF1PABPC1
Complex memberships
CCR4-NOT deadenylase complexYTHDF2–eIF3F–DDX1 translation complex

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2019 YTHDF2 binds m6A-modified mRNAs and decreases their half-life; in AML, YTHDF2 targets include Tnfrsf2 (TNF receptor) mRNA, whose upregulation upon Ythdf2 deficiency primes leukemic stem cells for apoptosis. m6A-seq, RNA stability assays, conditional knockout mouse models, human AML xenograft transplantation Cell stem cell High 31031138
2018 YTHDF2 directly binds m6A modification sites in the EGFR 3'-UTR and promotes EGFR mRNA degradation, suppressing MEK/ERK activation in hepatocellular carcinoma cells. m6A-RIP, RNA stability assay, overexpression/knockdown with downstream signaling readouts Cancer letters Medium 30423408
2019 YTHDF2 promotes decay of m6A-containing IL11 and SERPINE2 mRNAs in hepatocytes, and its transcription is repressed by HIF-2α; administration of a HIF-2α antagonist restores YTHDF2-dependent mRNA decay. m6A-IP with high-throughput sequencing, RNA stability assay, conditional hepatocyte knockout, HIF-2α antagonist (PT2385) treatment Molecular cancer High 31735169
2021 EGFR/SRC/ERK signaling phosphorylates YTHDF2 at serine 39 and threonine 381, stabilizing YTHDF2 protein; stabilized YTHDF2 promotes m6A-dependent decay of LXRA and HIVEP2 mRNAs in glioblastoma. Phosphorylation mapping by mass spectrometry, site-directed mutagenesis, RIP, m6A sequencing, in vivo tumorigenesis assay Nature communications High 33420027
2018 Conditional knockout of mouse Ythdf2 increases HSC numbers; knockdown of human YTHDF2 expands cord blood HSCs ex vivo by stabilizing m6A-marked mRNAs encoding transcription factors (e.g., Tal1) critical for self-renewal. Conditional KO mouse, limiting dilution transplantation, m6A-seq in HSPCs, siRNA knockdown rescue Cell research High 30065315
2021 YTHDF2 is SUMOylated in vivo and in vitro at K571; SUMOylation (induced by hypoxia) increases YTHDF2 binding affinity for m6A-modified mRNAs without affecting ubiquitination or localization, leading to enhanced mRNA degradation. In vitro SUMOylation assay, in vivo SUMOylation, site-directed mutagenesis (K571), m6A-RIP, mRNA stability assay Nucleic acids research High 33577677
2021 FBW7 E3 ubiquitin ligase directly interacts with YTHDF2, inducing its proteasomal degradation and thereby reducing YTHDF2-mediated BMF mRNA decay in ovarian cancer. IP-mass spectrometry, co-IP, western blot, in vitro and in vivo tumorigenesis assays, m6A-RIP-seq, RNA-seq Molecular cancer High 33658012
2019 YTHDF2 recognizes N1-methyladenosine (m1A)-modified sequences in addition to m6A; YTHDF2 depletion increases abundance of endogenously m1A-modified transcripts, indicating YTHDF2-dependent destabilization of m1A-containing mRNAs. Chemical proteomics pulldown, recombinant protein binding assay, YTHDF2 knockdown with transcript-level quantification ACS chemical biology Medium 31815430
2020 YTHDF2 promotes mRNA decay of WEE1 (a negative cell cycle regulator containing m6A) to accelerate mitotic entry; CDK1 activity stabilizes YTHDF2 protein, forming a CDK1–YTHDF2–WEE1 feedforward loop; CUL1, CUL4A, DDB1, and SKP2 E3 ligase components mediate YTHDF2 proteolysis. YTHDF2 siRNA depletion, m6A-seq, RNA stability assay, CDK1 inhibitor treatment, co-IP with E3 components PLoS biology High 32267835
2020 YTHDF2 and YTHDF3 are both required for somatic cell reprogramming; YTHDF2 recruits the CCR4-NOT deadenylase complex to promote deadenylation and mRNA clearance of somatic genes (e.g., Tead2, Tgfb1), facilitating mesenchymal-to-epithelial transition during iPSC generation. CRISPR/siRNA KD of Ythdf2/3 in reprogramming assay, scRNA-seq, co-IP with CCR4-NOT, mRNA stability assay Cell reports High 32905781
2021 YTHDF2 recognizes m6A-modified PER1 and TP53 mRNAs and promotes their degradation, contributing to ocular melanoma tumorigenesis driven by elevated histone lactylation. m6A-RIP, RNA stability assay, overexpression/knockdown in vitro and in vivo Genome biology Medium 33726814
2021 YTHDF2 is required for TNBC cell survival; disrupting YTHDF2-dependent mRNA degradation stabilizes MAPK pathway mRNAs, inducing EMT and increasing global translation, ultimately causing ER stress-induced apoptosis. Pooled CRISPR-Cas9 screen, eCLIP, m6A-seq, scRibo-STAMP, in vivo tumor models Molecular cell High 34216543
2023 O-GlcNAcylation of YTHDF2 at serine 263 (by OGT) enhances its protein stability by inhibiting ubiquitination; O-GlcNAcylated YTHDF2 stabilizes MCM2 and MCM5 mRNAs in an m6A-dependent manner to promote cell cycle progression. Co-IP, mass spectrometry, site-directed mutagenesis (S263), OGT inhibitor treatment, MeRIP, RNA stability assay Signal transduction and targeted therapy High 36765030
2021 Ythdf2-deficient HSCs chronically upregulate multiple m6A-modified inflammation-related transcripts, activating proinflammatory pathways; YTHDF2 is required to protect HSCs from inflammation-induced dysfunction and experimentally induced inflammation increases YTHDF2 expression. Conditional Ythdf2 KO mouse, serial transplantation, transcriptomic profiling, experimental inflammation induction The Journal of experimental medicine High 33156926
2023 YTHDF2 deficiency in tumor-associated macrophages (TAMs) reprograms them toward an antitumoral phenotype by targeting IFN-γ–STAT1 signaling; YTHDF2 expression in TAMs is regulated by IL-10–STAT3 signaling. Myeloid-specific Ythdf2 KO, flow cytometry, in vivo tumor models, STAT1/STAT3 signaling pathway analyses, TLR9-siRNA targeting Nature immunology High 36658237
2023 Ionizing radiation induces YTHDF2 expression in MDSCs via NF-κB signaling; YTHDF2 in turn directly binds and degrades transcripts encoding negative regulators of NF-κB, creating an IR–YTHDF2–NF-κB feedforward circuit. Myeloid-specific Ythdf2 KO, RNA-seq, m6A-RIP, in vivo tumor irradiation models, NF-κB inhibitor treatment Cancer cell High 37236197
2019 YTHDF2 knockdown in LPS-stimulated macrophages increases mRNA stability of MAP2K4 and MAP4K4, activating MAPK and NF-κB signaling to enhance proinflammatory cytokine expression. siRNA knockdown, mRNA stability assay, signaling pathway inhibitors, cytokine measurement International journal of molecular sciences Medium 30875984
2022 X-ray crystallography of small-molecule fragment ligands bound to the YTH domain of YTHDF2 revealed the m6A-binding pocket; fragment ligands compete with m6A-RNA for binding. X-ray crystallography, fluorescence-based competitive binding assay ACS medicinal chemistry letters High 36110386
2021 YTHDF2 mediates decay of m6A-modified CBS mRNA by binding within its CDS; in gastric cancer under hypoxia, lncRNA CBSLR interacts with YTHDF2 to enhance its binding to CBS mRNA, reducing CBS protein levels and leading to ferroptosis resistance. RIP, m6A-RIP, RNA stability assay, lncRNA pulldown, in vitro and in vivo cancer models Journal of advanced research Medium 35499052
2020 Mouse Ythdf2 knockout in spermatogonia leads to downregulated matrix metallopeptidase expression (Mmp3, Mmp13, Adamts1, Adamts9); m6A-IP-PCR and RIP-PCR confirm YTHDF2 binds and promotes degradation of these m6A-marked mRNAs, regulating cell adhesion and proliferation. CRISPR/Cas9 KO in spermatogonia, m6A-IP-PCR, RIP-PCR, rescue with Mmp13 inhibition Cell death & disease Medium 31959747
2023 YTHDF2 directly binds the m6A-modified CDS of DDX58 (RIG-I) mRNA and promotes its degradation; YTHDF2 depletion in bladder cancer stabilizes RIG-I, activating innate immune signaling and recruiting CD8+ T cells. MeRIP-seq, RNA-seq, RIP, RNA stability assay, in vivo orthotopic tumor model Cancer research High 36939388
2024 YTHDF2 facilitates translation of m6A-modified ETV5 mRNA by recognizing its 5'-UTR m6A and recruiting eIF3B, elevating ETV5 expression which transcriptionally induces PD-L1 and VEGFA in HCC. MeRIP-seq, RIP, co-IP with eIF3B, polysome profiling, in vivo HCC models Advanced science High 38247171
2022 YTHDF2 acts as a B cell-intrinsic factor required for GC B cell fate commitment; Ythdf2-deficient B cells fail to enter GCs because they cannot attenuate the plasmablast genetic program; YTHDF2 targets m6A-methylated plasmablast-regulating transcripts for decay. Conditional B-cell Ythdf2 KO, scRNA-seq, YTHDF2 binding site analysis, in vivo GC response Cell reports High 35508130
2023 YTHDF2 promotes miR-126 maturation from pre-miR-126 by recognizing m6A modification within pre-miR-126 and recruiting AGO2, a regulator of pre-miRNA processing, in AML cells. RIP, m6A-RIP on pre-miRNA, AGO2 co-IP, rescue with miR-126 overexpression Genes & diseases Medium 37588203
2021 Germ cell-specific Ythdf2 knockout mice are male sterile; YTHDF2 mediates timely clearance of phase-specific m6A-marked transcripts during spermatogenesis (differentiated spermatogonia to pachytene spermatocyte transition); loss of YTHDF2 leads to persistence of mRNAs mainly enriched in transcription regulation. Conditional KO (Vasa-Cre, Stra8-Cre), RNA-seq, YTHDF2-RIP-seq, MeRIP-qPCR, sperm functional assays Cell proliferation High 34850470
2023 HSP90β physically interacts with both YTHDF2 and the E3 ligase STUB1 in the cytoplasm, competitively inhibiting STUB1-mediated ubiquitination and degradation of YTHDF2, thereby stabilizing YTHDF2 protein in HCC. Co-IP, domain-mapping co-IP, ubiquitination assay, HSP90 inhibitor treatment Advanced science Medium 37515378
2021 PBRM1 (SWI/SNF component) interacts with YTHDF2 and is required for YTHDF2 binding to m6A-modified HIF-1α mRNA; YTHDF2 promotes HIF-1α mRNA translation rather than decay, and YTHDF2 depletion reduces HIF-1α protein. Co-IP, polysome/translation assay, m6A-RIP, siRNA depletion Cells Medium 34200988
2024 YTHDF2 promotes nuclear nascent RNA synthesis in CD8+ T cells in an m6A-recognition-dependent manner and interacts with IKZF1/3 to sustain transcription of their target genes; nuclear YTHDF2 also orchestrates chromatin changes promoting T cell polyfunctionality. T cell-specific KO, ChIP-seq, m6A-seq, YTHDF2 co-IP with IKZF1/3, nascent RNA assays, in vivo tumor models with lenalidomide rescue Nature communications High 39500904
2024 YTHDF2 functions as a dual reader: it destabilizes m6A-modified mRNAs (canonical) while stabilizing m5C-modified mRNAs by recruiting PABPC1, thereby enhancing expression and ATP synthesis in B cell malignancies. RIP-seq, m5C-seq, co-IP with PABPC1, mRNA stability assays, YTHDF2 overexpression/KO in B cell transformation models Cell High 39694037
2023 YTHDF2 promotes degradation of Hmox1 (heme oxygenase 1) mRNA in an m6A-dependent manner in alveolar macrophages, and myeloid-specific Ythdf2 KO elevates Hmox1, attenuating alternative macrophage activation and protecting from pulmonary hypertension. Myeloid-specific Ythdf2 KO (Lyz2-Cre), m6A-RIP, mRNA stability assay, Hmox1 inhibitor rescue, in vivo PH model Redox biology High 36801705
2024 YTHDF2 promotes m6A-dependent decay of TGF-β signaling pathway component mRNAs (ligands, receptors, transcription regulators) in hippocampal NSCs; Ythdf2 deletion elevates TGF-β signaling and increases quiescence acquisition. Conditional Ythdf2 KO in NSCs, m6A-seq, YTHDF2-RIP-seq, mRNA decay profiling, TGF-β pathway inhibitor rescue Cell stem cell High 39476834
2024 YTHDF2 forms a complex with eIF3F and DDX1 to enhance translation of m6A-modified mRNAs encoding microtubule-associated proteins, driving cancer progression and paclitaxel resistance independently of RNA decay. Co-IP (YTHDF2-eIF3F, YTHDF2-DDX1), polysome profiling, m6A-seq, RNA stability assay (ruling out decay), in vivo tumor models, virtual screening for inhibitor Molecular cell High 40480228
2024 YTHDF2 stabilizes Cx3cl1 (CX3CL1) mRNA in an m6A-dependent manner in peritumoral hepatocytes, facilitating CD8+ T cell recruitment; oxaliplatin upregulates YTHDF2 expression via cGAS-STING signaling. Liver-specific Ythdf2 KO mouse, tumor-bearing model, m6A-RIP, RNA stability assay, cGAS-STING pathway analysis Molecular cancer Medium 39237909
2024 Smooth muscle cell-specific Ythdf2 deficiency ameliorates pulmonary vascular remodeling; Ythdf2 paradoxically stabilizes Myadm mRNA in an m6A-dependent manner in PASMCs, promoting cell proliferation via suppression of the cell cycle inhibitor p21. SM-specific Ythdf2 KO (SM22α-Cre), proteomics, m6A-seq, RIP, mRNA stability assay, in vivo PH model Hypertension High 38832511
2024 YTHDF2 controls mRNA stability of the ubiquitin ligase ASB2 in skeletal muscle; muscle-specific YTHDF2 deletion impairs postnatal muscle growth and hypertrophic response by activating SMAD3-dependent TGF-β anti-growth program. Muscle-specific Ythdf2 KO, m6A-RIP, mRNA stability assay, SMAD3 readout, hypertrophy stimulus model Nature communications High 38467649
2023 YTHDF2 promotes degradation of m6A-modified DAPK3 mRNA by binding its 3'-UTR, driving gallbladder cancer progression and gemcitabine resistance. RIP-seq, MeRIP-seq, RNA-seq integration, RNA stability assay, in vitro/in vivo functional assays Cancer science Medium 37700438
2023 YTHDF2 binds m6A-modified Ythdf2/YTHDF2 mRNA as part of an autoregulatory loop in CD8+ T cells, reinforcing its own expression; this nuclear function requires m6A recognition by the YTH domain. m6A-seq, YTHDF2 nuclear localization demonstrated, domain mutagenesis, T cell-specific KO Nature communications Medium 39500904
2023 Ythdf2 binds m6A sites in STK11 mRNA and recruits AGO2 to form a silencing complex promoting STK11 mRNA degradation; loss of Ythdf2 stabilizes STK11, activates AMPK/mTOR, and impairs myoblast differentiation. Co-IP of Ythdf2-Ago2, RIP, m6A-RIP, RNA stability assay, AMPK/mTOR pathway readouts International journal of biological macromolecules Medium 37884231
2024 YTHDF2 mediates m6A-dependent degradation of SLC7A11 mRNA in Sertoli cells, as shown by RIP experiments demonstrating direct binding; this is exploited by BPF toxin to disrupt blood-testis barrier integrity. MeRIP, RIP, FTO overexpression/KD, in vivo/in vitro models Environmental pollution Low 38996995
2023 YTHDF2 promotes degradation of CDKN1B mRNA in an m6A-dependent manner in intrahepatic cholangiocarcinoma, identified by integration of RNA-seq, MeRIP-seq, and anti-YTHDF2 RIP-seq. MeRIP-seq, RNA-seq, anti-YTHDF2 RIP-seq integration, RNA stability assay, PDX model Clinical and translational medicine Medium 35696608
2023 YBX2 interacts with YTHDF2 through its cold-shock domain and recruits YTHDF2 to cytoplasmic granules; YTHDF2 knockdown ameliorates YBX2-induced HSPA6 mRNA destabilization in endometrial cancer cells. Co-IP, RNA pulldown, YTHDF2 KD rescue, mRNA stability assay Experimental cell research Low 37030331
2024 YTHDF2 cardiomyocyte-specific knockout drives cardiac dysfunction; YTHDF2 normally binds m6A-modified Myzap mRNA and controls its stability, and loss of YTHDF2 leads to upregulation of MYZAP, causing adverse cardiac remodeling. Cardiomyocyte-specific Ythdf2 KO, proteomics, m6A-RIP on Myzap mRNA, in vivo cardiac function measurements JACC. Basic to translational science Medium 37791304
2024 Lactylation of YTHDF2 (mediated by elevated lactate) increases its protein levels in cardiomyocytes; the intrinsically disordered region of YTHDF2 (not its m6A-binding activity) is required for its role in upregulating G3BP1 to control cardiomyocyte size and OGD/R-induced apoptosis. Lactylation detection, domain-deletion mutants lacking m6A binding, G3BP1 pathway readout, OGD/R cardiomyocyte model Basic research in cardiology Medium 38563985
2024 IFN-γ induces autophagic degradation of tumoral YTHDF2, sensitizing tumor cells to CD8+ T cell-mediated cytotoxicity; tumoral YTHDF2 deficiency promotes macrophage recruitment via CX3CL1 and enhances mitochondrial respiration in CD8+ T cells by impairing tumor glycolysis. Tumoral Ythdf2 KO, co-culture assays, autophagy inhibitors, metabolic assays, in vivo immunocompetent tumor models Science immunology High 38820140

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2021 Histone lactylation drives oncogenesis by facilitating m6A reader protein YTHDF2 expression in ocular melanoma. Genome biology 748 33726814
2019 Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia. Cell stem cell 406 31031138
2018 YTHDF2 suppresses cell proliferation and growth via destabilizing the EGFR mRNA in hepatocellular carcinoma. Cancer letters 295 30423408
2019 YTHDF2 reduction fuels inflammation and vascular abnormalization in hepatocellular carcinoma. Molecular cancer 286 31735169
2021 EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nature communications 243 33420027
2018 Suppression of m6A reader Ythdf2 promotes hematopoietic stem cell expansion. Cell research 231 30065315
2021 Hypoxia inducible lncRNA-CBSLR modulates ferroptosis through m6A-YTHDF2-dependent modulation of CBS in gastric cancer. Journal of advanced research 218 35499052
2019 m6A Reader YTHDF2 Regulates LPS-Induced Inflammatory Response. International journal of molecular sciences 193 30875984
2023 YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8+ T cells. Nature immunology 182 36658237
2023 YTHDF2 inhibition potentiates radiotherapy antitumor efficacy. Cancer cell 174 37236197
2021 SUMOylation of YTHDF2 promotes mRNA degradation and cancer progression by increasing its binding affinity with m6A-modified mRNAs. Nucleic acids research 155 33577677
2021 Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Molecular cell 148 34216543
2023 O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal transduction and targeted therapy 135 36765030
2020 METTL3/YTHDF2 m6 A axis promotes tumorigenesis by degrading SETD7 and KLF4 mRNAs in bladder cancer. Journal of cellular and molecular medicine 125 32126149
2021 The mRNA m6A reader YTHDF2 suppresses proinflammatory pathways and sustains hematopoietic stem cell function. The Journal of experimental medicine 117 33156926
2018 Epigallocatechin gallate targets FTO and inhibits adipogenesis in an mRNA m6A-YTHDF2-dependent manner. International journal of obesity (2005) 110 29795461
2021 FBW7 suppresses ovarian cancer development by targeting the N6-methyladenosine binding protein YTHDF2. Molecular cancer 106 33658012
2021 The biological function of m6A reader YTHDF2 and its role in human disease. Cancer cell international 105 33593354
2019 YTHDF2 Recognition of N1-Methyladenosine (m1A)-Modified RNA Is Associated with Transcript Destabilization. ACS chemical biology 93 31815430
2020 Activation of the KDM5A/miRNA-495/YTHDF2/m6A-MOB3B axis facilitates prostate cancer progression. Journal of experimental & clinical cancer research : CR 83 33087165
2023 The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response. Cancer research 81 36939388
2022 m6A binding protein YTHDF2 in cancer. Experimental hematology & oncology 77 35382893
2020 Decreased ALKBH5, FTO, and YTHDF2 in Peripheral Blood Are as Risk Factors for Rheumatoid Arthritis. BioMed research international 77 32884942
2021 FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner. Molecular therapy : the journal of the American Society of Gene Therapy 71 34915192
2020 YTHDF2, a protein repressed by miR-145, regulates proliferation, apoptosis, and migration in ovarian cancer cells. Journal of ovarian research 71 32948220
2020 YTHDF2/3 Are Required for Somatic Reprogramming through Different RNA Deadenylation Pathways. Cell reports 66 32905781
2021 Downregulation of microRNA-6125 promotes colorectal cancer growth through YTHDF2-dependent recognition of N6-methyladenosine-modified GSK3β. Clinical and translational medicine 63 34709763
2023 KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2-CXCL10 Axis in Colorectal Cancer. Cancer immunology research 62 37129929
2024 YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 61 38247171
2022 Gene amplification-driven RNA methyltransferase KIAA1429 promotes tumorigenesis by regulating BTG2 via m6A-YTHDF2-dependent in lung adenocarcinoma. Cancer communications (London, England) 61 35730068
2020 YTHDF2 promotes mitotic entry and is regulated by cell cycle mediators. PLoS biology 61 32267835
2022 YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. Clinical and translational medicine 60 35696608
2024 Betaine alleviates cognitive impairment induced by homocysteine through attenuating NLRP3-mediated microglial pyroptosis in an m6A-YTHDF2-dependent manner. Redox biology 57 38184996
2020 YTHDF2 promotes spermagonial adhesion through modulating MMPs decay via m6A/mRNA pathway. Cell death & disease 57 31959747
2021 KAT1 triggers YTHDF2-mediated ITGB1 mRNA instability to alleviate the progression of diabetic retinopathy. Pharmacological research 53 34098071
2023 HSP90β Impedes STUB1-Induced Ubiquitination of YTHDF2 to Drive Sorafenib Resistance in Hepatocellular Carcinoma. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 52 37515378
2021 YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML. Oncogene 52 33958724
2024 Exercise training decreases lactylation and prevents myocardial ischemia-reperfusion injury by inhibiting YTHDF2. Basic research in cardiology 51 38563985
2021 YTHDF2 Inhibits Gastric Cancer Cell Growth by Regulating FOXC2 Signaling Pathway. Frontiers in genetics 51 33505426
2024 The tumor-intrinsic role of the m6A reader YTHDF2 in regulating immune evasion. Science immunology 50 38820140
2020 FTO regulates ocular angiogenesis via m6A-YTHDF2-dependent mechanism. Experimental eye research 50 32531187
2021 N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma. Laboratory investigation; a journal of technical methods and pathology 46 33692441
2024 YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. Cell 45 39694037
2023 Ythdf2 promotes pulmonary hypertension by suppressing Hmox1-dependent anti-inflammatory and antioxidant function in alveolar macrophages. Redox biology 44 36801705
2021 YTHDF2 mediates LPS-induced osteoclastogenesis and inflammatory response via the NF-κB and MAPK signaling pathways. Cellular signalling 41 34089814
2022 YTHDF2 suppresses the plasmablast genetic program and promotes germinal center formation. Cell reports 40 35508130
2022 Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner. Gerontology 39 35468611
2021 m6 A reader protein YTHDF2 regulates spermatogenesis by timely clearance of phase-specific transcripts. Cell proliferation 38 34850470
2022 YTHDF2 promotes multiple myeloma cell proliferation via STAT5A/MAP2K2/p-ERK axis. Oncogene 37 35075244
2022 Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis. Cancer cell international 33 34996459
2024 PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration, invasion, and emt via the wnt-β-catenin pathway. Journal of experimental & clinical cancer research : CR 31 38637831
2023 Targeting YTHDF2 inhibits tumorigenesis of diffuse large B-cell lymphoma through ACER2-mediated ceramide catabolism. Journal of advanced research 31 37865189
2024 Foot-and-mouth disease virus VP1 degrades YTHDF2 through autophagy to regulate IRF3 activity for viral replication. Autophagy 30 38516932
2023 RNA m6A reader YTHDF2 facilitates precursor miR-126 maturation to promote acute myeloid leukemia progression. Genes & diseases 30 37588203
2022 YTHDF2 interference suppresses the EMT of cervical cancer cells and enhances cisplatin chemosensitivity by regulating AXIN1. Drug development research 30 35489084
2023 FTO-Nrf2 axis regulates bisphenol F-induced leydig cell toxicity in an m6A-YTHDF2-dependent manner. Environmental pollution (Barking, Essex : 1987) 29 36878272
2022 DDX5/METTL3-METTL14/YTHDF2 Axis Regulates Replication of Influenza A Virus. Microbiology spectrum 29 35583334
2022 Fragment Ligands of the m6A-RNA Reader YTHDF2. ACS medicinal chemistry letters 29 36110386
2024 YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment. Molecular cancer 28 39237909
2020 YTHDF2 Regulates Maternal Transcriptome Degradation and Embryo Development in Goat. Frontiers in cell and developmental biology 28 33117808
2020 Melatonin antagonizes ovarian aging via YTHDF2-MAPK-NF-κB pathway. Genes & diseases 28 35224163
2023 METTL3 facilitates immunosurveillance by inhibiting YTHDF2-mediated NLRC5 mRNA degradation in endometrial cancer. Biomarker research 26 37085864
2022 The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m6A RNA methylation reading protein Ythdf2. Cell death discovery 26 35383152
2023 YTHDF2-mediated regulations bifurcate BHPF-induced programmed cell deaths. National science review 25 38152479
2021 FTO regulates myoblast proliferation by controlling CCND1 expression in an m6A-YTHDF2-dependent manner. Experimental cell research 25 33651996
2023 Suppression of YTHDF2 attenuates autoimmune hepatitis by expansion of myeloid-derived suppressor cells. Journal of autoimmunity 24 36642058
2022 METTL3 promotes prostatic hyperplasia by regulating PTEN expression in an m6A-YTHDF2-dependent manner. Cell death & disease 24 35985997
2024 YTHDF2 upregulation and subcellular localization dictate CD8 T cell polyfunctionality in anti-tumor immunity. Nature communications 23 39500904
2023 N6-methyladenosine reader YTHDF2 promotes multiple myeloma cell proliferation through EGR1/p21cip1/waf1/CDK2-Cyclin E1 axis-mediated cell cycle transition. Oncogene 23 37012388
2023 Epitranscriptional regulation of TGF-β pseudoreceptor BAMBI by m6A/YTHDF2 drives extrinsic radioresistance. The Journal of clinical investigation 23 38099498
2024 m6A modification of VEGFA mRNA by RBM15/YTHDF2/IGF2BP3 contributes to angiogenesis of hepatocellular carcinoma. Molecular carcinogenesis 22 39092767
2022 Metformin combats obesity by targeting FTO in an m6A-YTHDF2-dependent manner. Journal of drug targeting 21 35481401
2022 PRKAA1, stabilized by FTO in an m6A-YTHDF2-dependent manner, promotes cell proliferation and glycolysis of gastric cancer by regulating the redox balance. Neoplasma 21 36305690
2023 Methyltransferase-like 3 aggravates endoplasmic reticulum stress in preeclampsia by targeting TMBIM6 in YTHDF2-dependent manner. Molecular medicine (Cambridge, Mass.) 20 36747144
2023 Mettl3/Ythdf2 regulate macrophage inflammation and ROS generation by controlling Pyk2 mRNA stability. Immunology letters 20 37952687
2023 RNA methylation reading protein YTHDF2 relieves myocardial ischemia-reperfusion injury by downregulating BNIP3 via m6A modification. Human cell 18 37500815
2022 YTHDF2 Inhibits the Migration and Invasion of Lung Adenocarcinoma by Negatively Regulating the FAM83D-TGFβ1-SMAD2/3 Pathway. Frontiers in oncology 18 35186724
2022 Expression and clinical significance of the m6A reader YTHDF2 in peripheral blood mononuclear cells from rheumatoid arthritis patients. Journal of immunotoxicology 18 35776431
2021 PBRM1 Cooperates with YTHDF2 to Control HIF-1α Protein Translation. Cells 17 34200988
2025 YTHDF2: a key RNA reader and antitumor target. Trends in immunology 16 40399203
2023 YTHDF2 promotes gallbladder cancer progression and gemcitabine resistance via m6A-dependent DAPK3 degradation. Cancer science 16 37700438
2023 Loss of YTHDF2 Alters the Expression of m6A-Modified Myzap and Causes Adverse Cardiac Remodeling. JACC. Basic to translational science 16 37791304
2025 YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 15 39823826
2025 Phenylpyrazoles as Inhibitors of the m6A RNA-Binding Protein YTHDF2. JACS Au 15 40017738
2023 YBX2 modulates mRNA stability via interaction with YTHDF2 in endometrial cancer cells. Experimental cell research 15 37030331
2024 FTO mediates bisphenol F-induced blood-testis barrier impairment through regulating ferroptosis via YTHDF1/TfRc and YTHDF2/SLC7A11 signal axis. Environmental pollution (Barking, Essex : 1987) 14 38996995
2022 YTHDF2 promotes temozolomide resistance in glioblastoma by activation of the Akt and NF-κB signalling pathways via inhibiting EPHB3 and TNFAIP3. Clinical & translational immunology 14 35582627
2025 The RNA-stability-independent role of the RNA m6A reader YTHDF2 in promoting protein translation to confer tumor chemotherapy resistance. Molecular cell 13 40480228
2024 lncRNA JPX Promotes Tumor Progression by Interacting with and Destabilizing YTHDF2 in Cutaneous Melanoma. Molecular cancer research : MCR 13 38441563
2024 BCLAF1 drives esophageal squamous cell carcinoma progression through regulation of YTHDF2-dependent SIX1 mRNA degradation. Cancer letters 12 38636894
2024 m6A/YTHDF2-mediated mRNA decay targets TGF-β signaling to suppress the quiescence acquisition of early postnatal mouse hippocampal NSCs. Cell stem cell 12 39476834
2021 YTHDF2 is essential for spermatogenesis and fertility by mediating a wave of transcriptional transition in spermatogenic cells. Acta biochimica et biophysica Sinica 12 34664060
2024 Nicotine-derived NNK promotes CRC progression through activating TMUB1/AKT pathway in METTL14/YTHDF2-mediated m6A manner. Journal of hazardous materials 11 38341886
2024 YTHDF2 governs muscle size through a targeted modulation of proteostasis. Nature communications 11 38467649
2024 METTL3 regulates cartilage development and homeostasis by affecting Lats1 mRNA stability in an m6A-YTHDF2-dependent manner. Cell reports 11 39088322
2024 Biological functions of the m6A reader YTHDF2 and its role in central nervous system disorders. Biochemical pharmacology 11 39424201
2023 YTHDF2 Regulates Cell Growth and Cycle by Facilitating KDM1A mRNA Stability. The American journal of pathology 11 36681189
2023 Ythdf2-mediated STK11 mRNA decay supports myogenesis by inhibiting the AMPK/mTOR pathway. International journal of biological macromolecules 11 37884231
2024 Smooth Muscle Ythdf2 Abrogation Ameliorates Pulmonary Vascular Remodeling by Regulating Myadm Transcript Stability. Hypertension (Dallas, Tex. : 1979) 10 38832511
2022 Novel insights into roles of N6-methyladenosine reader YTHDF2 in cancer progression. Journal of cancer research and clinical oncology 10 35763107